Thanks fletch, that's an excellent research summary. I
Thanks fletch, that's an excellent research summary. I haven't read that board in a long time so I would have missed that.
A couple of comments:
Studies have shown that there is a strong link between developing Parkinson's disease in middle age and chemical exposure at an earlier age. So it is not accurate to say that a genetic tendency is the ONLY possible cause. However it is possible that someone who did not have the genetic tendency would not developed Parkinson's, but might have had other bad effects -- or no effects -- from the same chemical exposure. As the poster said, the human body is an incredibly complex system and I doubt that we'll know absolute causes and mechanisms in the lifetime of anyone reading this board today.
As far as the amyloid theory, I think that the reason that all the drugs trying to clear out amyloid plaques have FAILED or made things worse is indeed the band-aid theory --
the brain's defense against the disease is to form the plaques, the way that clots form to stop bleeding from a cut. When you get rid of the plaques, it's like ripping the clots off a cut -- the bleeding starts again. That would explain why some of the experimental drugs ACCELERATED the decline for patients.
And, for both Parkinson's and Alzheimer's, I think that future research will show that some people who have been diagnosed with those diseases have other diseases that have similar symptoms, and have been lumped into the category together. Particularly with Alzheimer's, there is radical difference between people in symptoms, speed of decline, and the way that it affects personality while they are still somewhat functional. Some people who were previously normal-behaving people become angry and violent; others who may have been angry or nasty before become nicer and less nasty when they get the disease.
I think that there are many different causes for dementia systems, and lumping them all together in the category of "Alzheimer's" is another reason why so many clinical trials have had mixed results. If you're testing a drug for one disease on people who have different types of disease, that drug is only going to help the ones who have the disease you're trying to treat.
We desperately need a test for Alzheimer's that can diagnose it in the living. Fortunately it looks like there is some progress in that direction. The sooner, the better.
1
Anavex Life Sciences Corp. (AVXL) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...
Continue Reading
AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...
Continue Reading
GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...
Continue Reading
AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...
Continue Reading
Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...
Continue Reading
Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....
Continue Reading
Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...
Continue Reading
Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...
Continue Reading
In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...
Continue Reading
Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...
Continue Reading
Top 5 Most Recently Viewed Articles
Revolutionizing Cultivated Meat Production through Collaboration Stämm has recently announced an exciting collaboration with SuperMeat to accelerate developments in cultivated meat biomanufacturing. With Varana Capital's strategic backing, this partnership seeks to enhance SuperMeat's cultivated chicken production process using Stämm's innovative bioreactor...
Continue Reading
Manchester United Reports Its Fourth Quarter Results Manchester United PLC (NYSE: MANU) has recently released its fiscal fourth-quarter results for 2024. The numbers show a significant year-on-year sales drop of 15.0%, totaling 142.2 million British pounds, or about $179.43 million. Unfortunately, this result didn't meet analysts' expectations, which had projected sales...
Continue Reading
China's Rural Road Achievements and Future Vision Recently, the State Council Information Office of China unveiled an insightful white paper titled "China's Rural Roads in the New Era." This document highlights the incredible accomplishments and future aspirations concerning rural road development in the country. The white paper reveals that by the end of 2023, China's...
Continue Reading
Overview of Fourth Quarter Results Tyson Foods, Inc. (NYSE: TSN), recognized as one of the largest food companies in the world, has showcased impressive financial performance for the fourth quarter of 2025. The company reported sales of $13,860 million, marking a 2.2% increase compared to the corresponding quarter in the previous year. When excluding legal contingency...
Continue Reading
Good Cheer Captures the Victory in Kentucky Oaks Excitement filled the air as Good Cheer claimed a notable victory in the Longines Kentucky Oaks, a highlight of the horse racing calendar. This remarkable race saw Good Cheer emerge victorious in a challenging environment with sloppy track conditions, competing against a strong field of 13 fillies. Record-Worthy Wagering at...
Continue Reading